Israeli Concenter BioPharma Announced as a 2018 TiE50 Finalist
Apr. 24, 2018
Concenter BioPharma has been selected as a "2018 TiE50 Finalist" for the prestigious TiE50 Awards Program recognizing the world's most innovative tech startups. This awards competition is part of TiE Inflect 2018, the world's largest conference for tech entrepreneurs.
"We are honored and excited to have been chosen as a finalist out of over 7000 companies from around the world! Our plan is to begin clinical trials for our Type 2 Diabetes drug in the coming months," said Dror Chevion, Co-Founder and CEO of the company.
Concenter BioPharma developed a novel, protected PLATFORM of drugs for proven treatments of multiple indications. Members of its platform assist in treating the causes and/or symptoms of multiple indications. Potential Clinical Applications include: CNS Injury and Degenerative Diseases, Inflammatory skin disorders, Inflammatory Pulmonary diseases, Type 2 diabetes and its complications, and more.
TiE50 has become a global brand that attracts thousands of tech startups worldwide. This year, we screened more than 7400 companies from 28 countries and selected the best-of-breed as our "2018 TiE50 Finalists". These companies are finalists in the ultimate runoff for the 50 winners.
TiE Inflect (previously TiEcon) is the world's largest conference for entrepreneurs and intrapreneurs with participation from top technology companies, leading venture capital firms, and global services providers. TiEcon 2017 attracted 5400+ attendees from across the world - including CEOs of established companies to first-time entrepreneurs creating new companies, to leading investment professionals and corporate executives.
The Indus Entrepreneurs (TiE) is a not-for-profit founded in 1992 in the Silicon Valley. TiE is the world's largest network of tech entrepreneurs. We are a cohesive global network with a footprint of half million entrepreneurs, enterprise executives, investment professionals, and other accomplished individuals. We operate from 60 cities in 18 countries.